JOINN has established hundreds of validated animal disease models covering oncology, central and peripheral nervous systems, cardiovascular and metabolic disorders, autoimmune diseases, digestive diseases, hematological diseases, reproductive and endocrine systems, dermatology, and infectious diseases.
Leveraging its dual-track service platform (GLP-accredited system and flexible Non-GLP study modules), JOINN provides customized end-to-end study solutions from early-stage screening through IND-enabling studies. It enables triple validation of candidate drugs prior to clinical entry: key pharmacodynamic verification, mechanism-of-action investigation, and safety assessment.
Metabolic Disease Models
DMetabolic diseases are highly prevalent worldwide. Preclinical research imposes stringent requirements on model specificity, stability and translational value.
| Disease | Models | Species |
| Obesity | Diet-induced obesity (DIO), spontaneous obesity | Rats/Mice (including genetically modified animals), non-human primates (NHPs) |
| Type 1 Diabetes Mellitus | STZ-induced T1DM | Rats/Mice, NHPs |
| Type 2 Diabetes Mellitus | Induced model: STZ+HFD Spontaneous model: db/db mice, ZDF rats, cynomolgus monkeys Hyperinsulinemic-euglycemic clamp | Rats/Mice Beagle dogs |
| Hyperlipidemia / Hypercholesterolemia | Induced: high-fat high-sugar diet Spontaneous: hypertriglyceridemia, Lp(a)emia; ApoE mice, golden hamsters, NHPs | Mice, golden hamsters, NHPs |
| Atherosclerosis | High-fat high-sugar diet induction; high-fat high-sugar diet combined with mechanical vascular injury | ApoE mice, rabbits, NHPs |
| Hyperuricemia | Spontaneous hyperuricemia, induced hyperuricemia | UOX mice, SD rats, NHPs |
Diabetic Complication Models
Metabolic diseases are highly prevalent worldwide. Preclinical research imposes stringent requirements on model specificity, stability and translational value.
| Disease | Models | Species |
| Diabetic Nephropathy | STZ + nephrectomy + high-salt challenge | Rats |
| Impaired Diabetic Wound Healing | STZ-induced T1DM plus skin excision; T2DM plus skin excision | Rats, db/db mice, ZDF rats |
| Diabetic Neuropathic Pain | STZ-induced T1DM | Mice |
Central & Peripheral Nervous System Disease Models
Central and peripheral nervous system diseases feature complicated pathological mechanisms and limited clinical treatment options. Preclinical evaluation requires strict standards for model specificity, stability and neurological function assessment. Joinn Labs has a dedicated team led by neuropharmacology experts. Supported by advanced neurobehavioral platforms, telemetric EEG recording and molecular testing technologies, we build a panel of nervous system disease models with strong translational potential. We comprehensively assess neuroprotective, analgesic, anti-epileptic and other activities of drug candidates and investigate mechanisms of action; all data is suitable for global IND filings.
| Disease | Models | Species |
| Alzheimer’s Disease | APP/PS1 transgenic mice, 5XFAD transgenic mice | Mice |
| Parkinson’s Disease | 6-OHDA-induced PD model, MPTP-induced PD model, A53T transgenic mice | Mice, Rats, NHPs |
| Depression / Anxiety | Forced swim test, tail suspension test, open field test, elevated plus maze, m-CPP-induced anxiety-like behavior | Rats/Mice |
| Epilepsy | PTZ-induced acute & chronic epilepsy (rats); kainic acid intrahippocampal chronic epilepsy (NHPs) | Rats, NHPs |
